How has Poly Medicure (POLYMED) been performing? We dig into revenue, profitability, valuation, and ownership trends.
Poly Medicure Revenue Trend
Poly Medicure's top line grew 21.4% to ₹1,670 Cr in FY2025, compared to ₹1,376 Cr in FY2024.
A 15.6% revenue CAGR over 10 years is hard to ignore. Poly Medicure's top line moved from ₹390 Cr to ₹1,670 Cr in that period.
At ₹1,670 Cr in annual revenue, Poly Medicure is one of the mid-sized players in the healthcare space.
Looking at the year-on-year numbers, Poly Medicure has seen 10 years of unbroken revenue growth.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹1,670 Cr | +21.4% |
| FY2024 | ₹1,376 Cr | +23.4% |
| FY2023 | ₹1,115 Cr | +20.8% |
| FY2022 | ₹923 Cr | +17.4% |
| FY2021 | ₹786 Cr | — |
View Poly Medicure's full 10-year revenue trend with CAGR analysis →
Poly Medicure Profitability
A 31.1% improvement in net profit took Poly Medicure's bottom line to ₹339 Cr in FY2025.
Cost discipline paid off, with net profit margin expanding to 20.3% from 18.8%.
Diluted EPS stood at ₹34.11 in FY2025, compared to ₹26.90 in FY2024.
Is Poly Medicure Undervalued
Poly Medicure shares are currently trading at ₹1,727.90.
Craytheon calculates intrinsic value using the P/E Ratio and EPS Growth models. Both appear in the Valuation Models cards below.
Valuation Models
Poly Medicure Shareholding Pattern
Promoter holding has remained stable at 62.4% over the past 4 quarters, indicating confidence in the company's direction.
On the foreign institutional side, the holding is 5.6% as of June 2026 — down from 9.8%.
Domestic institutional investors (DIIs) held 16.1% as of June 2026, up from 13.5% a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 62.4% | 5.6% | 16.1% | 15.9% |
| Mar 2026 | 62.4% | 5.9% | 15.6% | 16.1% |
| Dec 2025 | 62.4% | 9.4% | 13.8% | 14.3% |
| Sep 2025 | 62.4% | 9.8% | 13.5% | 14.3% |
Track quarterly shareholding changes for Poly Medicure →
Poly Medicure Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹31.92B (up 71.8% YoY from ₹18.59B).
Top categories: Property, Plant & Equipment (35.3%), Cash & ST Investments (33.4%), Receivables (11.0%).
Of the ₹31.92B in liabilities and equity, 86.6% is shareholder equity, 5.6% is interest-bearing debt, and 7.7% is operating liabilities. Over the year, debt is up 3.6% and equity is up 88.1%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 10.65B |
| Receivables | 3.50B |
| Inventories | 2.86B |
| Property, Plant & Equipment | 11.28B |
| Investments | 205.12M |
| Intangibles & Goodwill | 551.95M |
| Other Assets | 2.88B |
| Category | Value |
|---|---|
| Equity | 27.66B |
| Short-term Debt | 1.79B |
| Long-term Debt | 7.71M |
| Trade Payables | 864.19M |
| Other Liabilities | 1.60B |
Poly Medicure Key Highlights
Pulling it all together, here's what the numbers say about Poly Medicure (POLYMED) heading into the next fiscal year.
Revenue of ₹1,670 Cr in FY2025, up 21.4% year-over-year.
Long-term revenue has been compounding at 15.6% annually over 10 years.
The company is profitable, with a net margin of 20.3% and net income of ₹339 Cr.
Unlock Full Analysis
Want to dig deeper? Craytheon's platform provides 10 years of financial data, three valuation models, and insider trading activity for Poly Medicure.